Pharmacogenomics in lung cancer chemotherapy: A review of what the oncologist should know

Anticancer Research

Volumn 34, Issue 10, 2014, Pages 5241-5250

  D'Antonio, Chiara ^a   Milano, Annalisa ^a   Righini, Riccardo ^a   Onesti, Concetta Elisa ^a   Bassanelli, Maria ^a   Falcone, Rosa ^a   Paris, Ida ^a   Lauro, Salvatore ^a   Marchetti, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cisplatin; Gemcitabine; Lung cancer chemotherapy; Pemetrexed; Pharmacogenomic; Polymorphism patents; Taxanes; Vinorelbine

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ABC TRANSPORTER; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTOCHROME P450; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE; OXALIPLATIN; PEMETREXED; REPLICATION FACTOR A; TAXANE DERIVATIVE; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP C PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; DNA ADDUCT; DNA BINDING PROTEIN; ENDONUCLEASE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; DNA ADDUCT; DNA POLYMORPHISM; DNA REPAIR; DRUG INACTIVATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; GENE MUTATION; GENETIC ANALYSIS; GENETIC TRAIT; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG CANCER; MEMBRANE TRANSPORT; META ANALYSIS (TOPIC); NON SMALL CELL LUNG CANCER; ONCOLOGIST; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENOMICS; PROGRESSION FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ACTIVE TRANSPORT; DRUG EFFECTS; DRUG RESISTANCE; GENETIC POLYMORPHISM; GENETICS; LUNG NEOPLASMS; META ANALYSIS; METABOLISM; PHARMACOGENETICS;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; DNA ADDUCTS; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; HUMANS; LUNG NEOPLASMS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84917691462     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Brunton LL, Parker K L, Blumenthal D and Buxton I: The Goodman & Gilman's manual of pharmacology and therapeutics. 11th Edition. The McGraw-Hill Companies: New York 2008.
2. Nagasubramanian R, Innocenti F and Ratain MJ: Pharmacogenetics in cancer treatment. Annu Rev Med 54: 437-452, 2003.
3. Relling MV and Dervieux T: Pharmacogenetics and cancer therapy. Nat Rev Cancer 1(2): 99-108, 2001.
4. Innocenti F and Ratain MJ: Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer 38(5): 639-644, 2002.
5. Lazarou J, Pomeranz BH and Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta- analysis of prospective studies. JAMA 279(15): 1200-1205, 1998.
6. Johnson JA and Bootman JL: Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 155(18): 1949-1956, 1995.
7. Heiner C, Nordman ES and Woudenberg TM: Compositions and methods for clonal amplification and analysis of polynucleotides. WO 2006099579 A2, 2006.
8. Nyren P, Ronaghi M and Tallsjoe A: Method of sequencing DNA. WO 2002020836 A2, 2002.
9. Gelfand DH, Holland PM, Saiki RK and Watson RM: Reaction mixtures for detection of target nucleic acids. US 5804375 A, 1998.
10. Kirst M, Ribeiro De Resende MF, JR, Gomide Neves L, Dervinis C and Balmant KM: Method for genome complexity reduction and polymorphism detection. US 20130035238 A1, 2013.
11. Giovannetti E, Toffalorio F, De Pas T and Peters GJ: Pharmacogenetics of conventional chemotherapy in non small cell lung cancer: a changing landscape? Pharmacogenomics 13(9): 1073-1086, 2012.
12. Ferté C, Gomez Roca C, Loriot Y, Bahleda R, Moldovan C, Cohen A, Izzedine H, Soria JC and Ederhy S: Reversible cardiogenic shock following 5-fluorouracil infusion. Invest New Drugs 28(4): 531-533, 2010.
13. Yamayoshi Y, Iida E and Tanigawara Y: Cancer pharmacogenomics: international trends. Int J Clin Oncol 10(1): 5-13, 2005.
14. Marck PC, Gandara DR and Lara PN: Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the "common arm" approach. Expert Rev Anticancer Ther 12(12): 1591-1596, 2012.
15. Evans WE and McLeod HL: Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348( 6): 538-549, 2003.
16. Marsh S and McLeod HL: Cancer pharmacogenetics. Br J Cancer 90(1): 8-11, 2004.
17. Lockhart AC, Tirona RG and Kim RB: Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther 2(7): 685-698, 2003.
18. Cascorbi I and Haenischn S: Pharmocogenetics of ATP-binding cassette transporters and clinical implications. Methods Mol Biol 596: 95-121, 2010.
19. Hirouchi M, Suzuki H, Itoda M, Ozawa S, Sawada J, Ieiri I, Ohtsubo K and Sugiyama Y: Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm Res 21(5): 742-748, 2004.
20. Han B, Gao G, Wu W, Gao Z, Zhao X, Li L, Qiao R, Chen H, Wei Q, Wu J and Lu D: Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non small cell lung cancer patients. Lung Cancer 72(2): 238-243, 2011.
21. Sun N, Sun X, Chen B, Cheng H, Feng J, Cheng L, Fenq J, Cheng L and Lu Z: MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 65(3): 437-446, 2010.
22. Iguchi A: Probe, polymorphism detection method, method of evaluating drug efficacy or tolerance, and reagent kit. US 20120282608 A1, 2012.
23. Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema AD, Beijnen JH and Schellens JH: Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 118(9): 2466-2475, 2012.
24. Lu C, Spitz MR, Zhao H, Dong Q, Truong M, Chang JY, Blumenschein GR Jr, Hong WK and Wu X: Association between glutathione S-transferase polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer 106(2): 441-447, 2006.
25. Booton R, Ward T, Heighway J, Aschcroft L, Morris J and Thatcher N: Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non small cell lung cancer. J Thorac Oncol 1(7): 679-683, 2006.
26. Li W, Yue W, Zhang L, Zhao X, Ma L, Yang X, Zhang C, Wang Y and Gu M: Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients. Lung 190(1): 91-98, 2012.
27. Sreeja L, Syamala V, Hariharan S, Syamala VS, Raveendran PB, Sivanandan CD, Madhavan J and Ankathil R: Glutathione S-transferase M1, T1 and P1 polymorphisms: susceptibility and outcome in lung cancer patients. J Exp Ther Oncol 7(1): 73-85, 2008.
28. Gonlugur U, Pinarbasi H, Gonlugur TE and Silig Y: The association between polymorphisms in glutathione S-transferase (GSTM1 and GSTT1) and lung cancer outcome. Cancer Invest 24(5): 497-501, 2006.
29. Sweeney C, Nazar-Stewart V, Stapleton PL, Eaton DL and Vaughan TL: Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 12(6): 527-533, 2003.
30. Ali-Osman F, Ballard L, Keller C and Lemmons R: High throughput detection of glutathione s-transferase polymorphic alleles. WO 2004036179 A2, 2004.
31. Marsin S, Vidal AE, Sossou M, Menissier-de Murcia J, Le Page F, Boiteux S, de Murcia G and Radicella JP: Role of XRCC1 in the coordination and stimulation of oxidative DNA damage repair initiated by the DNA glycosylase hOGG1. J Biol Chem 278(45): 44068-44074, 2003.
32. Raymond E, Faivre S, Chaney S, Woinarowski J and Cvitkovic E: Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1(3): 227-235, 2002.
33. Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J and Yingfenq Z: Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 65(2): 230-236, 2009.
34. Duell EJ, Holly EA, Bracci PM, Whiencke JK and Kelsey KT: A population-based study of the Arg399Gln polymorphism in Xray repair cross- complementing group 1 (XRCC1) and risk of pancreatic adenocarcinoma. Cancer Res 62(16): 4630-4636, 2002.
35. Goode EL, Ulrich CM and Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11(12): 1513-1530, 2002.
36. Wang Y, Spitz MR, Zhu Y, Dong Q, Shete S and Wu X: From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair (Amst) 2(8): 901-908, 2003.
37. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS and Christiani DC: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22(13): 2594-2601, 2004.
38. Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, Grossi F, Recchia F, Zanelli F, Fontanini G, Naldi N, Campanini N, Azzoni C, Bordi C and Ardizzoni A: Bio-FAST trial Group: ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer 108(8): 1695-1703, 2013.
39. Wu J, Liu J, Zhou Y, Ying J, Zou H, Guo S, Wang L, Zhao N, Hu J, Lu D, Jin L, Li Q and Wang JC: Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clin Cancer Res 18(14): 3972-3981, 2012.
40. Wang Z, Xu B, Lin D, Tan W, Leaw S, Hong X and Hu X: XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. Lung Cancer 62(1): 99-104, 2008.
41. Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Sun Y, Zhang XR, Xu BH and Lin DX: XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 28(3): 196-199, 2006.
42. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T and Soria JC; IALT Bio Investigators: DNA repair by ERCC1 in non-smallcell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10): 983-991, 2006.
43. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Tarón M, Sánchez JJ, Danenberg KD, Danenberg PV and Rosell R: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8(7): 2286-2291, 2002.
44. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Vinolas N, Paz-Ares L, Lopez-Vivanco G, Munoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D and Prosell R: Customizing cisplatin based on quantitative excision repair cross complementing I mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25(19): 2747-2754, 2007.
45. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L and Christiani DC: Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10(15): 4939-4943, 2004.
46. Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, Wain JC, Neuberg D, Liu G and Christiani DC: Polymorphisms in ERCC1 and grade 3 or 4 toxicity in nonsmallnon small cell lung cancer patients. Clin Cancer Res 11(4): 1534-1538, 2005.
47. Tseden-Ish M, Choi YD, Cho HJ, Ban HJ, Oh IJ, Kim KS, Song SY, Na KJ, Ahn SJ, Choi S and Kim YC: Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype. Respirology 17(1): 127-133, 2012.
48. Viguier J, Boige V, Miquel C, Pocard M, Girandeau B, Sabourin JC, Ducreux M, Sarasin A and Praz F: ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11(17): 6212-6217, 2005.
49. Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC and Hwang TS: Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44(3): 311-316, 2004.
50. Lenz HJ, Stoehlmacher J and Park (Jong-Han) D: Polymorphisms in the ERCC1 gene for predicting treatment outcome. US 7662553 B2, 2010.
51. Lenz HJ, Stoehlmacher J and Park (Jong-Han) D: Polymorphisms for predicting disease and treatment outcome. EP 2385137 A1, 2011.
52. Zhao M, Li X, Xing C and Zhou B: Association of methylenetetrahydrofolate reductase C677T and A1298C polymorphisms with colorectal cancer risk: a meta-analysis. Biomed Rep 1(5): 781-791, 2013.
53. Zhu N, Gong Y, He J, Xia J and Chen X: Influence of Methylenetetrahydrofolate Reductase C677T Polymorphism on the Risk of Lung Cancer and the Clinical Response to Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer: An Updated Meta-Analysis. Yonsei Med J 54(6): 1384-1393, 2013.
54. Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N and Groen HJ: Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer J Clin Oncol 27(12): 2038-2045, 2009.
55. Mak RH, Alexander BM, Asomaning K, Heist RS, Liu CY, Su L, Zhai R, Ancukiewicz M, Napolitano B, Niemirko A, Willers H, Choi NC and Christiani DC: A single nucleotide polymorphism in the MTHFR (methylene tetrahydrofolate reductase) gene is associated with risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy. Cancer 118(14): 3654-3665, 2012.
56. Hirai M and Kozuka M: Primer set for amplification of mthfr gene, mthfr gene amplification reagent comprising same, and use of same. WO 2011062258 A1, 2011.
57. Lepper ER, Nooter K, Verweij J, Acharya RM, Figg WD and Sparreboom A: Mechanisms of resistance to anticancer drug:the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 6(2): 115-138, 2005.
58. Bergman AM, Pinedo HM, Talianidis I, Veerman G, Loves WJ, Van der Wilt CL and Peters GJ: Increased sensitivity to Gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 88(12): 1963-1970, 2003.
59. Takara K, Sakaeda T and Okumura K: An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 12(3): 273-286, 2006.
60. Wei HB, Hu J, Shang LH, Zhang YY, Lu FF, Wei M and Yu Y: A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer. Chin Med J (Engl) 125(16): 2902-2907, 2012.
61. Kasuya K, Tsuchida A, Nagakawa Y, Suzuki Y, Suzuki M, Aoki T, Abe Y, Shimazu M and Sofuni A: Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by genetic polymorphism analysis. Hepatogastroenterology 59(117): 1609-1613, 2012.
62. Kuwano M and Wada M: SNPs in 5' regulatory region of MDR1 gene. WO2005028645A1, 2006.
63. Single nucleotide polymorphism detection kit for G2677T / A of MDR1. CN102816845 A, 2012.
64. Ross DD and Nakanishi T: Impact of breast cancer resistance protein on cancer treatment outcomes. Methods Mol Biol 596: 251-290, 2010.
65. Zhang YY, Liu Y, Zhang JW, Ge GB, Wang LM, Sun J and Yang L: Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epipaclitaxel. Xenobiotica 39(4): 283-292, 2009.
66. Xie HG, Wood AJ, Kim RB, Stein CM and Wilkinson GR: Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5(3): 243-272, 2004.
67. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN Jr., Coltman CA Jr., Fukuoka M, Saijo N, Fukushima M and Mach PC: Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics J Clin Oncol 27(21): 3540-3546, 2009.
68. Sadee W and Wang D: Polymorphism in CYP3A4 gene affecting drug metabolizing and uses thereof. WO 2010111600 A1, 2010.
69. Chattopadhyay S, Moran RG and Goldman ID: Pemetrexed: biochemical and cellular pharmacology, mechanisms and clinical applications. Mol Cancer Ther 6(2): 404-417, 2007.
70. Nief N, Le Morvan V and Robert J: Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel. Eur J Cancer 43(5): 955-962, 2007.
71. Jung M, Lee CH, Park HS, Lee JH, Kang YA, Kim SK, Chang J, Kim DJ, Rha SY, Kim JH and Cho BC: Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. Yonsei Med J 54(4): 854-864, 2013.
72. Li WJ, Jiang H, Fang XJ, Ye HL, Liu MH, Liu YW, Chen Q, Zhang L, Zhang JY, Yuan CL and Zhang QY: Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy. Oncol Lett 5(4): 1165-1170, 2013.
73. Marsh S and McLeod HL: Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer 1(3): 179-181, 2001.
74. Danenberg KD: Methods of determining a chemotherapeutic regimen based on loss of heterozygosity at the thymidylate synthase locus. CA 2517384 C, 2013.
75. Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N and Groen HJ: Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced Non Small cell lung cancer. JCO 27: 2038-2045, 2009.
76. Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ and Ardizzoni A: Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer 78(1): 92-99, 2012.
77. Kajita J, Kuwabara T, Kobayashi H and Kobayashi S: CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Durg Metab Dispos 28(9): 1121-1127, 2000.
78. Chou FC, Tzeng SJ and Huang JD: Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab Dispos 29(9): 1205-1209, 2001.
79. Pan JH, Han JX, Wu JM, Sheng LJ and Huang HN: CYP450 polymorphisms predict clinical outcomes to vinorelbine-based chemotherapy in patients with Non-small cell lung cancer. Acta Oncol 46(3): 361-366, 2007.
80. Woodahl EL and Ho RJ: The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 5(1): 11-19, 2004.
81. Viñolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sánchez-Torres JM, Barón FJ, Cobo M, Maestu I, Moreno I, Mesia C, Izquierdo A, Felip E, López-Brea M, Marquez A, Sánchez-Ronco M, Tarón M, Santarpia MC and Rosell R; Spanish Lung Cancer Group : Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 71(2): 191-198, 2011.
82. Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN and Yu QZ: MDR1 Single Nucleotide Polymorphisms Predict Response to Vinorelbine-Based Chemotherapy in Patients with Non Small Cell Lung Cancer. Respiration 75(4): 380-385, 2008.
83. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Schäkel U, Ehninger G and Schaich M: MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62(17) : 4955-4962, 2002.
84. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz P, Burk O, Decker J, Alken P, Rothenpieler U, Kerb R, Hoffmeyer S and Brauch H: Association of the glycoprotein transporter MDR1C3435T polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 13(7): 1847-1854, 2002.
85. Ishikawa T, Sakurai A and Tamura A: Method for detection of gene polymorphism and method for screening of substance. WO 2007026940 A1, 2007.